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Decreased postheparin lipolytic activity in renal transplant recipients
with cyclosporin A. The patterns of hyperlipidemia in renal transplant
recipients (RTRs) are more variable than in the uremic state, showing
increases in both very low-density lipoprotein (VLDL) and low density
lipoprotein (LDL). This has been attributed, at least in part, to
immunosuppressive therapy, especially to treatment with corticoste-
roids. Postheparin lipolytic activity (PHLA) was determined in 28
RTRs. Sixteen patients presenting with hyperlipidemia comprised
group A, who were aged 49.8 13.5 years, and had a cholesterol of 8.24
1.86 mmol/liter, triglycerides of 6.02 3.33 mmollliter. Twelve
patients presenting cholesterol and triglyceride values within the nor-
mal range were in group B, and were aged 48.6 13.3 years. All RTRs
received cyclosporin A (CsA) twice daily orally, which were divided in
two equal doses and adjusted to provide CsA blood trough levels (RIA)
in a range of 250 to 350 ng/nil. Twenty-one RTRs were additionally
treated by alternate-day corticosteroids, whereas seven patients had
CsA on their sole immunosuppressive agent. PHLA (mol free fatty
acids/mllhr, given 10 and 20 mm after 100 U/heparmn kg body wt
intravenously) was commonly reduced in RTRs (group A at 10/20 mm:
5.6 1.1/5.26 1.2; group B: 8.26 2.91/8.38 3.44) as compared to
the values obtained in healthy controls (15.3 2.9/17.2 5.0). This was
mainly due to a reduction of the activity of the hepatic triglyceride
lipase, and to a minor extent to a reduced activity of peripheral
lipoprotein lipase. There was no statistically significant difference of
PHLA in RTRs with or without corticosteroid treatment. Postheparin
lipolytic activity is commonly decreased in renal transplant recipients.
This effect does not depend on low corticosteroid administration, but
may be caused by CsA medication.
Serum lipid abnormalities are common in uremia and persist
after renal transplantation [1—8]. It is assumed that these
changes relate to the high incidence of atherosclerotic vascular
disease in these patients, since about 40% of deaths after kidney
transplantation are due to cardiovascular disease [9, 10].
Hyperlipoproteinemia in chronic renal failure (CRF) is char-
acterized by an increase in serum total and very low-density
lipoprotein (VLDL) triglycerides (Tg), a reduction in plasma
high density lipoprotein (HDL) and normal or even subnormal
serum total and low density lipoprotein (LDL) cholesterol [11],
and is present in 40 to 60% of these patients [11—131.
Postheparin lipolytic activity (PHLA) has been shown to be
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reduced in CRF, mainly due to a decrease in hepatic triglycer-
ide lipase (HTGL) activity [ii, 12], which correlates with
kinetic studies which demonstrate a reduced fractional removal
rate in VLDL triglycerides [11, 14].
A great part of the recently reported improvement in clinical
outcome in patients with kidney transplants is attributed to the
introduction, of the immunosuppressive medication, cyclospo-
rifle (CsA) [14, 15]. However, this drug has also demonstrated
a variety of nonimmunologic toxic side effects, like nephrotox-
ity and hepatotoxity [14]. In addition, patterns of hyperlipi-
demia in renal transplant recipients are more variable than in
the uremic state, with increased VLDL and LDL levels also
being attributed in part to immunosuppressive therapy, in
particular to corticosteroids [16—20]. However, data of PHLA
in successfully kidney transplanted patients are only available
for patients treated with corticosteroids and/or azathioprine
who show no abnormality [1, 11, 21].
In contrast, hypertriglyceridemia can be observed in up to
76% of renal transplant recipients (RTRs) taking CsA [8].
Recently, administration of CsA has been claimed to be
related to alterations of lipid and carbohydrate metabolism [1—8,
21—25], with improvement of hyperlipidemia following CsA
intoxication [23] as well as after replacement of CsA by
azathioprine treatment [2, 5]. The hydrolysis of triglycerides in
the plasma is affected by two lipid ester hydrolases acting
selectively, and released by heparin [26-3 1] from their tissue
receptor bindings at the capillary endothelium. Total posthep-
ann lipolytic activity (PHLA) results from the activation by
both hepatic triglyceride lipase (HTGL) and adipose tissue
lipoprotein lipase (LPL), which requires apolipoprotein (apo)
C-lI [32] for activation, and can be inhibited by NaCI and
protamine sulfate or selectively by specific antibodies [33—37].
LPL hydrolyzes triglycerides of chylomicrons and very low-
density lipoprotein (VLDL) in extrahepatic tissues; it is par-
tially responsible for the plasma concentrations of high density
lipoproteins (HDL and HDL2). HTGL is present on liver
sinusoids and is thought to act by remoVing TG from VLDL and
other particals of decreasing size, but has also been assumed to
take part in the elimination of cholesterol from the circulation
[38]. Lack of LPL activity is associated primarily with chylo-
micronemia, whereas TG, LDL and HDL values are within the
normal range [39—41]. Patients lacking HTGL activity have
elevated TG levels in both LDL and HDL and abnormal
VLDL, /3-VLDL, pre-/3-VLDL in their plasma [30].
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Table 1. Plasma lipid fractions in RTRs before and 20 minutes after
heparin administration
0 20 Minutes P
Group A
Total cholesterol mmol/liter 8.24 1.86 7.77 2.15 NS
HDL 0.88 0.23 0.87 0.23 NS
LDL 6.4 1.8 5.93 1.9 NS
VLDL 1.14 0.49 1,08 0.39 NS
Cholesterol:HDL 9.56 2.5 9.54 3.3 NS
Total triglycerides mmol/liter 6.02 3.33 5.54 3.28 < 0.0005
VLDL-TG 1.94 0.84 1.67 0.72 0.05
Group B
Total cholesterol mmol/liter 5.57 1.19 5.25 1.15 NS
HDL 1.15 0.39 1.16 0.36 NS
LDL 4.07 1.35 3.88 0.97 NS
VLDL 0.32 0.12 0,27 0.17 NS
Cholesterol:HDL 5.3 1.8 4.96 1.6 NS
Total triglycerides mmol/liter 1.84 0.39 1.43 0.38 <0.0005
VLDL-TG 0.66 0.24 0.53 0.27 0.05
Group C
Total cholesterol mmol/liter 4.2 0.85 3.98 0.9 NS
HDL 1.29 0.15 1.29 0.15 NS
LDL 3.19 0.6 3.13 0.54 NS
VLDL 0.16 0.06 0.14 0.05 NS
Cholesterol:HDL 3.43 0.86 3.16 0.75 NS
Total triglycerides inmol/liter 1.15 0.45 0.70 0.32 < 0.0005
VLDL-TG 0.27 0.13 0.16 0.08 <0.0005
Group A was hyperlipidemic RTRs (N = 16); Group B was normo-
lipidemic RTRs (N = 12); Group C was healthy subjects (N = 10).
In view of the suggested association between hyperlipopro-
teinemia and advanced atherosclerotic vascular lesions [42—441,
the present study was undertaken to examine whether the
common state of hyperlipidemia in renal transplant recipients
(RTRs) is due to a decreased PHLA and is related to the mode
of immunosuppressive treatment.
Methods
Patients
Twenty-eight renal transplant recipients (RTRs) were inves-
tigated. Sixteen had hyperlipidemia (group A: mean age 49.8
13.5 years; 8 women and 8 men), whereas 12 presented with
cholesterol and triglyceride values within the normal range
(Group B: mean age 48.6 13.3 years; 4 women, 8 men). Ten
metabolically healthy subjects (Group C: mean age 30 6
years; 4 women, 6 men) served as controls (Table 1).
None of the RTRs had a history of diabetes prior to trans-
plantation, but one nonobese RTR group A patient (BMI 23.1
kg!m2) developed type 2 diabetes mellitus following transplan-
tation, which required dietary restrictions and low dose sulfo-
nylurea treatment and was followed by a reduction of HbAlc
from 6.7% to 5.6%. No further subject was taking any drugs
affecting glucose or lipid metabolism, such as oral contracep-
tives, other estrogenic compounds, diuretics or lipid lowering
drugs. Six RTRs in group A and 5 RTRs in group B received
a-blockers as their antihypertensive medication. All subjects
were of stable weight and transplant function for at least two
months before the study. RTRs with proteinuria exceeding 0.5
g/day and patients with a post-transplant period less than six
months or with hepatic disease were excluded from the study.
The average time after transplantation was 28.8 18 months
(6 to 60 months) for RTRs in group A and 22 22 months (6 to
86 months) for those in group B, (NS).
All patients received cyclosporin A (CsA) orally twice daily,
divided in two equal doses which were adjusted to maintain
CsA blood trough levels (RIA) of 250 to 350 nglml. All blood
samples were drawn in the morning before administration of
CsA in a fasting (12 hours) state. Twenty-one RTRs were
additionally treated by alternate-day corticosteroids (mean
prednisone dose: 6.25 3.5 mg/day; range 15.5 to 5.0 mg/day),
whereas seven patients (4 group A + 3 group B) had CsA as
their sole immunosuppressive agent.
RTRs presenting with hyperlipidemia were placed on a diet
with the goal to reduce elevated cholesterol and triglyceride
levels for at least three months before entering to the study.
The study protocol was approved by the institutional review
board, and all subjects gave written informed consent before
entering the study.
Laboratory methods
Blood glucose (BG), creatinine (normal < 99.1 mol/liter),
cholesterol (normal < 5.18 mmol/liter) and triglycerides (normal
< 2.0 mmollliter) were measured using an autoanalyzer
(Greiner G-300). HbA1C (normal range < 5.8%) was deter-
mined using the BlO-Rad method (Richmond, California,
USA). Thyroxine and triiodthyronine were determined by a
radioimmunoassay (Becton Dickinson, New Jersey, USA).
Endogenous insulin reserve was assessed by measuring C-pep-
tide levels in the fasting state in 14 group A and 12 group B
patients. Serum C-peptide values (normal range 1.2 to 2.8
nglml) were determined as previously described [45].
Lipoprotein lipids were measured according to the Lipid
Research Clinic (LRC) methods [46]. Very low-density lipopro-
teins (VLDL) were removed by ultracentrifugation (d < 1.006
g/ml), low density lipoproteins (LDL) were separated from the
infranatant (d < 1.063 gJml) by heparin and polyanion precipi-
tation using manganese chloride, and HDL cholesterol was
determined from the supernatant.
Lipoprotein lipase and hepatic lipase were released into the
circulation in patients and controls after an overnight fast by
intravenous heparin injection (100 lU/kg body weight) as de-
scribed by Krauss, Levy and Fredrickson [47]. Before, 10 and
20 minutes after rapid heparin administration blood was drawn
from an antecubital vein into glass tubes containing 0.1 M
sodium oxalate and put on ice until centrifugation. The plasma
was immediately separated at 4°C by centrifugation at 3000 rpm
for 10 minutes and promptly frozen at —70°C until analysis.
PHLA assay
Postheparin lipase activity was determined by a modification
of the method of Krauss, Levy and Fredrickson [47]. The
substrate consisted of 35 sCi glycero-trioleate [9,10 (n)- H], 4
mg unlabeled glycero-trioleate, 0.1 M Tris-HC1 (pH 8.6), 2%
bovine serum albumin (Sigma Chemical Co., St. Louis, Mis-
souri, USA; 98% free fatty acid negative) in a final volume of
11.5 ml. This mixture was sonicated with a Branson Sonifier-
Cell Disruptor at 100 W for 4 x 1 minute on ice with a one
minute intermission to prevent the substrate from overheating.
For analysis. 20 .d of plasma was added to 260 d of freshly
sonicated substrate and incubated for 20 minutes at 37°C.
Duplicate plasma samples were preincubated in 1 M NaCI in
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order to determine hepatic triglyceride lipase after inhibition of
LPL. The reaction was stopped by addition of 3.25 ml of a
mixture of chloroformimethanolln-heptane (1:1.28:1.37; you
vo!) and 1.05 ml of 0.1 M K2C031H3B03 (pH 10.5).
Free fatty acids were extracted by vortexing this mixture for
15 seconds. The phases were separated by centrifugation at 4°C
and 3000 rpm for 20 minutes. One milliliter of the upper phase
was added to 10 ml of Hydrofluor (Beckman Instruments, Palo
Alto, California, USA).
Total lipase activity was estimated as the amount of free fatty
acids released per minute of incubation at 37°C. HTGL activity
was calculated as the difference between total postheparin
lipase activity and salt-inhibited (LPL) activity, that is, PHLA
- LPL = HTGL.
Data analysis
All values are expressed as means SD. Intergroup (groups
A, B, C) comparisons were done by one way analysis of
variance followed by Tukey's multiple range comparison test,
or the Student's t-test for unpaired data, as appropriate [48, 49].
All results of the one way of analysis of variance were con-
firmed by multiple ANOVA to adjust for any changes related to
age and gender [48].
Values were classified to be not significant (NS) if P values
were > 0.05.
Comparisons of lipolytic enzyme activity were made at 10
and 20 minutes after heparin injection, since lipase activity is
virtually absent at baseline conditions. For lipid turnover the
values at baseline conditions were compared to that obtained at
20 minutes after heparin injection.
Results
Cyclosponn A blood trough levels (RIA) were similar in
hyperlipidemic and normolipidemic RTRs (group A: 325 48
ng/ml; group B: 321 58 ng/ml; NS).
Serum creatinine was similar in RTRs of groups A and B
(114.4 30.5 vs. 125.8 36.6 jsmoLlliter; NS) and 88.4 12.7
p,mollliter for the control group.
Serum albumin values were within the normal range in all
RTRs. Mean proteinuria was 0.31 0.12 g/day.
All patients had normal thyroid hormone levels (group A:
S-T4/S-T3: 8.1 2.3 jsg/dlIl.23 0.28 ngldl; group B: 7.89
2.5 jsgldl/ll.2 0.3 ng/dl; NS) and normal HbAlc (<5.8%)
values.
Serum immunoreactive C-peptide was 4.01 1.5 in group A
and 4.12 1.7 nglml in group B patients (NS), respectively.
Mean body mass index (kg/m2) was comparable for RTRs and
controls (group A: 24.6 1.4; group B: 22.8 1.5; group C:
23.2 1.7; NS).
All RTRs presented with weight gain as compared to the
hemodialysis period (group A: +3.86 1.5 kg; group B: +4.16
1.3 kg; NS).
Group A
Sixteen RTRs presented with severe hyperlipidemia (Table
1). All of them had a marked hypertnglyceridemia and 12 had
moderately elevated cholesterol values too. Classification was
as follows: fasting chylomicronemia (type V hyperlipoprotein-
emia, N 2); elevated triglycerides (type IV hyperlipoprotein-
emia, N = 10) and elevated cholesterol and triglycerides (type
lib hyperlipoproteinemia, N = 4).
Group B
Total serum cholesterol and triglyceride values in RTRs of
this group were normal (cholesterol < 5.18 minol/liter, Tg <
2.0), but nevertheless triglyceride values were higher (+62.5%)
than those seen in the control group. This was due to an
elevation in VLDL-TG (+ 144%) versus controls (Table 1).
PHLA was zero at baseline (before heparin injection) and
rose following heparin administration. Thus, PHLA was less
after 10 and 20 minutes in group A patients (36.6%130.5%)than
in controls (P < 0.0001). Normolipidemic RTRs had a signifi-
cant higher PHLA (+48%/+59%; figure 1) than RTRs of group
A (P <0.002) at both occasions but still —85% to — 105% less
than the control group (P < 0.001; Fig. 1).
In RTRs of both groups LPL activity was higher at 10 than at
20 minutes after heparin stimulation (Fig. 2) but this difference
did not reach levels of significance. In controls LPL activity at
10 minutes was 16% higher as in group B RTRs (NS) and 85%
higher (P < 0.0005) than in hyperlipidemic RTRs (group A). An
increase in LPL activity was obtained in controls 20 minutes
after stimulation (Fig. 2; +58%, P < 0.005) and was signifi-
cantly higher as in RTRs (vs. group A: +354%; P < 0.0001; vs.
group B: +206%; P < 0.006).
HTGL activity was greater in controls at 10 and 20 minutes
after heparin administration than in RTRs (Fig. 3), and some-
what higher in normolipidemic than in hyperlipidemic RTRs
(group A vs. group B: 10 mm., +35.5%, NS; 20 mm.: +26%
NS). Thus, in RTRs of group B HTGL activity was only 40% at
10 minutes and 41% at 20 minutes (P < 0.0005) of the HTGL
activity of the control group (Fig. 3). Hyperlipidemic RTRs
presented with lower HTGL values being only 29% at 10
minutes and 32% at 20 minutes (P < 0.0005) of that determined
in the control group (Fig. 3).
Serum triglyceride (Table 1) and VLDL triglyceride values
(Fig. 4) fell following heparin injection. Observed Tg reduction
was 40.2 6.7% in healthy subjects and this was more than in
RTRs (group A: 25.1 12,5%, P < 0.005, and group B: 21.8
12.1%, P < 0.02). This effect was associated with a smaller
decrease of VLDL triglycerides (baseline vs. 20 mm values) in
RTRs (group A: —14 8%; NS; group B: —19.7 9%; NS)
than in controls (—40.7 6%; Table 1; P < 0.005).
Mean HDL cholesterol levels were lower in RTRs (A: 0.88
0.23 mmollliter; B: 1.15 0.39 mmol/liter; A vs. B: P < 0.007)
than in healthy subjects (1.29 0.15 mmol/liter; P <0.009).
HDL cholesterol values were unaffected by heparin stimula-
tion, whereas total LDL and VLDL cholesterol slightly de-
creased.
Table 2 shows that patients with and without additional
steroid treatment did not differ in regards to plasma cholesterol,
triglycerides and lipolytic enzyme activity.
For evaluation of various influences on postheparin lipolytic
activity a multiple analysis of variance over the entire study
group adjusted for age and gender as a covariate was per-
formed. A highly significant influence between groups and time
point of serial measurements (P < 0.001) was obtained. The
influence of age on HTGL at 10 minutes was of borderline
statistical significance (P < 0.048). However, for HTGL at 20
minutes and the other parameters (LPL, PHLA at both time
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measurements) there was no significant influence of either age
or gender.
Discussion
The present study demonstrates that hyperlipidemic and even
normolipidemic RTRs present with a markedly reduced post-
heparin lipolytic activity (Figs. I to 3), although plasma total
cholesterol and triglycerides were only above normal in a
subgroup of RTRs (group A). As normal values of PHLA have
been described in RTRs immunosuppressed with corticoste-
roids and azathioprine [11, 13, 50, 51] in line with reports on
adverse effects of cyclosporin A on lipoprotein metabolism
[1—8, 20—24] the phenomenon reported in the presented study
seem to be associated with cyclosporin A therapy.
Although RTRs grouped B presented with total cholesterol
and triglyceride values within the normal range they had higher
total triglycerides and VLDL triglycerides as compared to that
reported by the lipid research clinics for age-matched healthy
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Fig. 1. Totalpostheparin lipolytic activity (PHLA) 10
and 20 minutes after heparin injection (100 U/kg body
wt). Symbols are: (•) renal transplant recipients with
severe hyperlipidemia (group A); (A) RTRs with normal
cholesterol and triglyceride values (group B); (0)
healthy subjects (group C). Intergroup differences at
I 10/20 minutes: P < 0.05 for PHLA between A vs. B at
20 both occasions; and P < 0.001 for PHLA between A vs.
B and B vs. C at both occasions.
controls [46]. Concomitantly, HDL cholesterol values were
reduced in all RTRs (P < 0.005) resulting in an increased total
cholesteroLlHDL ratio a condition commonly found in patients
lacking PHLA [11, 26, 27].
LPL has been reported to be reduced in type lib, III, IV and
V hyperlipoproteinemia as well as in patients with renal failure
[26, 27, 52, 53] or hypothyroidism [30]. However, all patients
studied presented with both euthyroidism and stable renal
transplant function (serum creatinine < 191 molIliter). No
correlation was seen between serum creatinine and PHLA.
A different pattern of response of LPL following heparin
administration was observed in RTRs. Thus, we found a sharp
decrease of LPL activity in RTRs grouped A at 10 and 20
minutes following heparin injection, whereas RTRs of group B
demonstrated only slight reduced LPL activity at 10 minutes as
compared to the control group. However, only in controls LPL
activity increased significantly 20 minutes after stimulation. The
lack of rise in RTRs indicates a different kinetics of this
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Fig. 2. Lipoprotein lipase values (LPL) before and
20 minutes after heparin injection (100 U/kg body
wi). Symbols are: (•) renal transplant recipients
with severe hyperlipidemia (group A); (A) RTRs
with normal cholesterol and triglyceride values
(Group B); (0) healthy subjects (Group C).
Intergroup differences at 10/20 minutes: P < 0.05/P
<0.001 for LPL between A vs. C; NS/P < 0.05 for
LPL between B vs. C.
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Fig. 3. Hepatic triglyceride lipase values (HTGL)
before and 20 minutes after heparin injection (100 U/kg
body wt). Symbols are: Group A, Severely
_______________
hyperlipidemic RTRs (•); B, normolipidemic RTRs (A);
I I C, healthy subjects (0). Intergroup differences at 10/2010 20 minutes: P < 0.005 for HTGL between A vs. C and B
vs. C at both occasions.
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Fig. 4. VLDL triglyceride values before and 20 minutes after heparin
injection (100 U/kg body wt). Symbols are: (•—•) renal transplant
recipients (RTRs) with severe hyperlipidemia; (A—A) RTRs with
normal cholesterol and triglyceride values; and (0—0) healthy
subjects.
enzyme. This effect is comparable with data reported in patients
with acute renal failure who presented with accelerated enzyme
inactivation and severe hypertriglyceridemia [52, 53].
In accordance with other studies [12, 13, 28, 29, 31, 40, 41]
our results confirm that a decrease in PHLA is associated with
a decreased triglyceride "clearing reaction" in RTRs of both
group A and B, affecting VLDL TG in particular (Fig. 4).
The reported values for PHLA activity differ markedly
among various studies [11, 28, 36, 41, 47, 54-56], and even
variations of reference values within the same laboratory have
been described [11,41,53,57]. These facts emphasize the need
for special reference values drawn individually for each inves-
tigation and for each laboratory [11]. However, values de-
scribed for normal subjects [11, 13, 26, 28, 30, 36, 38, 41, 52, 53]
are in agreement to that obtained in our control group, whereas
the values obtained in CsA treated RTRs were comparable to
the decreased values described for patients maintained on
chronic hemodialysis treatment [11, 13, 51]. In particular,
similar values for normal controls aged 43 years have been
reported earlier for our laboratory [53] and by Applebaum-
Bowden et al in a population with a median age of 52 years [41].
However, in the present study patients and controls were not
the same age. We therefore performed extensive statistical
analysis over the entire study population in order to exclude
possible effects of age on PHLA, showing that PHLA and LPL
activity were not significantly correlated with either age or
Table 2. Total postheparin lipolytic activity (PHLA) 10 and 20
minutes after heparin stimulation in cyclosporin A treated RTRs
without prednisone treatment (N = 7) and in those on additional
corticosteroid medication (N = 21; mean prednisone dose/day
6.25 3.5 mg)
Cortisone treatment
PWithout With
Cholesterola 6.54 1.6 6.47 1.8 NS
mmol/lirer
Triglyceride? 3.26 2.5 3.47 2.3 NS
mmol/liter
PHLA 10b 6.9 1.6 6.7 2.7 NS
PHLA 20b 5.9 1.7 6.8 3.1 NS
HTGL 10" 3.2 1.7 4.0 2.8 NS
HTGL 20b 3.2 1.7 3.6 1.6 NS
LPL IO 3.8 1.7 3.0 1.5 NS
LPL 20b 2.8 1.2 3.47 2.3 NS
a At baseline conditionsb smoi free fatty acids/mi/hr
gender. However, there was a weak correlation with age and
HTGL 10 minutes after heparin administration. This observa-
tion is in accordance with a previous report demonstrating the
same results for men but not for women [41]. Furthermore, it
has been shown that the influence of age on PHLA is very
small, comparing the PHLA activity of young (mean age 26
years) and elderly men (mean age 86 years) after low- and
high-dose heparin stimulation [55]. As compared to the group of
young men, differences obtained in the elderly men following
low dose heparin disappeared after high dose administration of
heparin [55]. Thus, unresponsiveness to heparin stimulation has
been attributed to be responsible for the lower activity follow-
ing administration of low dose heparin in the elderly patients
[55].
However, Huttunen et al reported a significant decrease of
LPL according to age and male sex, whereas no difference
according to age was obtained for HTGL, which was signifi-
cantly higher in men than in women [54]. In total, the values
reported for the activity of postheparin plasma lipases in normal
subjects exceeded the values measured in our control group
[54].
The mechanisms responsible for hyperlipidemia in organ
transplant recipients are rather uncertain, and an association
between corticosteroid medication and serum cholesterol
and/or triglyceride levels has been assumed to be due to
induced peripheral insulin resistance [13, 17], but these results
were not confirmed by others [20, 56]. Since different doses of
steroids were given, interpretation of studies with a positive
correlation between the degree of hypertriglyceridemia and the
steroids administered is difficult, as patients with impaired graft
function were not excluded [13] and uremia alone usually is
associated with hyperlipidemia [52, 53].
Thus, we found no correlation between PHLA and steroid
exposure in RTRs (Table 2). The same result was obtained for
13-blockers given to 11 RTRs. RTRs who had steroid therapy
received this medication on alternate days and in low dosages,
both known to be accompanied by a reduction in the production
rate and plasma concentration of lipoproteins [6, 16, 18].
CsA has been suggested to be diabetogenic due to p cell
0 20 0 20
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toxicity [2, 5, 24, 25] and to enhance prednisone metabolism,
thereby inducing peripheral insulin resistance [19].
All RTRs studied presented with high C peptide values, by
this unaffected endogenous insulin reserve has to be assumed.
However, cortisol-induced insulin resistance by impaired sup-
pression of glucose production and stimulation of glucose
utilization due to a postreceptor defect [57] is not rebutted by
the normal blood glucose and libAic values obtained in our
patients. However, although not appropriate for diagnosis of
insulin resistance, it might even be estimated by the high fasted
C-peptide values as found in the RTRs. As insulin is a major
regulator of lipolytic enzymes [58, 591 the role of insulin
resistance, which commonly is associated with high circulating
insulin values and hypertriglyceridemia [60], on decreased
lipolytic enzyme activity has to be elucidated.
In addition to the discussed side effects of cyclosporin A on
insulin activity, the decrease in PHLA might be explained by
tissue-specific effects on lipoprotein lipase mRNA transcription
as seen at high concentrations [14]. Thus, a recent study gave
strong evidence that an increase in lipoprotein lipase activity
was accompanied by elevation of the lipoprotein mRNA [61].
A close relationship between LPL activity and weight loss in
obese patients was described [61]. Therefore, RTRs with severe
obesity (body mass index > 26 kglm2) or excess weight gain
after transplantation (>7 kg) were excluded from our study.
Proteinuria greater than 3.5 g/day has been demonstrated to
play a role in the deranged cholesterol and triglyceride metab-
olism [62]. Therefore, RTRs with a proteinuria exceeding 0.5
glday were excluded from the study.
Although hypertriglyceridemia prevailed elevated LDL cho-
lesterol values were common in RTRs of group A. HTGL has
been assumed to contribute to the elimination of cholesterol
from circulation [38]; the main pathway for the entrance of LDL
into cells is managed by a cell surface receptor [63]. Recent
reports give evidence that there is a close relationship between
the LDL receptor and the transport of CsA across the cell
membrane through receptor-mediated endocytosis of CsA-con-
taming LDL particles [64, 65]. Furthermore, the presence of a
messenger RNA for LDL receptors in the brain and spinal cord
has been reported [66]. CsA-induced CNS toxicity has been
speculated to be mediated by areas of densely composed cells
which are able to express the LDL receptor [64]. Thus, an
adverse effect of CsA on the transcription of mRNA [67] might
explain both the reduced production of PHLA, by this inducing
hypertriglyceridemia, and reduced LDL elimination.
In conclusion, our data demonstrate that hypertriglyceri-
demia in RTRs is closely related to a decrease in PHLA. This
adverse effect seems to be mediated predominantly by CsA
medication.
Further investigations will be necessary to clarify the inter-
ference of CsA with postheparin lipolytic activity and associ-
ated hyperlipoproteinemia.
Reprint requests to K. Derfier, M.D., I. Medical Department, Divi-
sion of Nephrology, University of Vienna, Lazarettgasse 14, A-1090
Vienna, Austria.
References
I. CHAN MK, VARGHESE Z, MOORHEAD JF: Lipid abnormalities in
uremia, dialysis and transplantation. Kidney mt 19:625—637, 1981
2. HARRIS KPG, RUSSELL 01, PARVIN SD, VEITCH PS, WALLS J:
Alterations in lipid and carbohydrate metabolism attributable to
cyclosporin A in renal transplant recipients. (abstract) Brit Med J
292: 16, 1986
3. HODEL K, MORDSINI RC, BRUNNER F, LANDMANN J, THIEL 0:
Cyclospsorin A (CyA) and hyperlipidemia after renal transplanta-
tion. Kidney mt 25:984—985, 1984
4. HODEL K, M0IWSINI RC, BRUNNER FP, THIEL JG: Cyclosporin A
und Hyperlipidamie nach Nierentranspiantation. Schweiz Med
Wschr 116:885—888, 1986
5. VERSLUIS DJ, WENTING GJ, WEIMAR W: Alterations in lipid and
carbohydrate metabolism attributable to cyclosporin A in renal
transplant recipients. Brit Med J 292:272, 1986
6. TURGAN C, RUSSELL 01, BAKER F, WALLS J: The effect of renal
transplantation with a minimal steroid regime on uraemic hyper-
triglyceridaemia. Quart J Med 210:271—277, 1984
7. ETTINGER WH, BENDER L, GOLDBERG AP, HAZZARD WR: Lipo-
protein lipid abnormalities in healthy renal transplant recipients:
Persistence of low HDL2 cholesterol. Nephron 47:17—21, 1987
8. DERFLER K, BALCKE P. K0P5A H, STOCKENHUBER F: Is cyclos-
porine A therapy associated th hyperlipidemia in transplant recip-
ients? (abstract) Xth International Congress of Nephrology Lon-
don, 1987, p. 610a
9. BRUNNER FP, BROYER M, BRYNGER H, CHALLAH S, DYKES SR.
FASSBINDER W, OULES R, RIzzoNi 0, SELWOOD NH, WING AJ:
Registry report: Survival on renal replacement therapy: Data from
the EDTA registry. Nephrol Dial Transplant 2:109—122, 1988
10. BROWN KA, RIMMER J, HAISCH C: Noninvasive cardiac risk
stratification of diabetic and nondiabetic uremic renal allograft
candidates using dipyridamole-thallium-20l imaging and radionu-
clide ventriculography. Am J Cardiol 1:1017—1021, 1989
11. TASKINEN MR: Lipoprotein lipase in hypertriglyceridemias, in
Lipoprotein Lipase, edited by BORENSZTAJN J, Chicago, Evener
Publishers, 1987, pp. 201—228
12. CHAN MK, PERSAUD J, VARGHESE Z, MOORHEAD JF: Pathogenetic
roles of post-heparin lipases in lipid abnormalities in hemodialysis
patients. Kidney mt 24:812—818, 1984
13. IBELS LS, SIM0NS LA, KING JO, WILLIAMS PF, NEALE FC,
STEWART JH: Studies on the nature and causes of hyperlipidemia in
uraemia, maintenance dialysis and renal transplantation. Quart J
Med 50:149—160, 1981
14. KAHAN BD: Drug therapy: Cyclosporine. N EngI J Med 321:1725—
1738, 1989
15. THOMPSON AW: Cyclosporin. Mode of Action and Clinical Appli-
cations. Dordrecht/Boston/London, Kluwer Academic Publishers,
1989
16. ZIMMERMANN J, FAINARU M, EISENBERG S: The effects of pred-
nisone therapy on plasma lipoproteins and apolipoproteins: A
prospective study. Metabolism 33:521—526, 1984
17. CHAN MK, VARGHESE Z, PERSAUD JW, FERNANDO ON, MooR-
HEAD JF: The role of multiple pharmaco-therapy in the pathogen-
esis of hyperlipidemia after renal transplantation. Clin Nephrol
15:309—313, 1981
18. CATTRAN DC, STEINER G, WILSON DR, FENTON SSA: Hyperlipi-
demia after renal transplantation: Natural history and pathophysi-
ology. Ann mt Med 91:554—559, 1979
19. OST L: Effects of cyclosporin on prednisone metabolism. Lancet
25:451, 1984
20. KASISKE B, UMEN AJ: Persistent hyperlipidemia in renal transplant
patients. Medicine 66:309—316, 1987
21. BALLANTYNE CM, JONES PH, PAYTON-ROSS C, PATSCH W, SHORT
HD III, NOON GE', Gorro AM JR, DEBAKEY ME, YOUNGJB:
Hyperlipidemia following heart transplantation: Natural history
and intervention with Mevinolin (Lovastatin). Transplant Proc
4:60—62, 1987
22. LOWRY RP, SOLTYS 0, MANGEL R, KWITEROWITCH P. SNIDER-
MANAD: Type II hyperlipoproteinemia, hyperapobetalipoproteine-
mia, hyperalphalipoproteinemia following renal transplantation:
Prevallence and precipitating factors. Transplant Proc 19:2229—
2232, 1987
23. NEMUNATTIS J, DEEG HJ, YEE GC: High cyclosporin levels after
bone marrow transplantation associated with hypertriglyceridemia.
Lancet ii:744—745, 1986
Derfier et a!: PHLA in transplantation 727
24. DRESNER LS, ANDERSEN DK, KAHNG KU, MuN5HI IA, WAIT RB:
Effects of cyclosporine on glucose metabolism. Surgery 106:163—
170, 1989
25. BENDING JJ, Ooa CS, VIBERTI GC: Diabetogenic effect of cyclos-
porin. Brit Med J 294:401—402, 1987
26. ECKEL RH: Adipose tissue lipoprotein lipase, in Lipoprotein Li-
pase, edited by BORENSZTAJN J, Chicago, Evener Publishers, 1987,
pp. 79—132
27. ECKEL RH: Lipoprotein lipase: A multifunctional enzyme relevant
to common metabolic diseases. N Eng! J Med 16:1060—1068, 1989
28. ILLINGWORTH DR, ALAM SA, ALAM NA: Lipoprotein lipase and
hepatic lipase activity after heparin administration in abetalipopro-
teinemia and hypobetalipoproteinemia. Metabolism 32 (Suppl. 9):
869—873, 1983
29. NICOLL A, LEWIS B: Evaluation of the roles of lipoprotein lipase
and hepatic lipase in lipoprotein metabolism: In vivo and in vitro
studies in man. Eur J Clin Invest 10:487—495, 1980
30. VALDERMARSSON 5, NILSSON-EHLE P: Hepatic lipase and the
clearing reaction: Studies in euthyroid and hypothyroid subjects.
Horm Metabol Res 19:28—30, 1987
31. ROBINSON DS, FRENCH JE: Heparin, the clearing factor lipase and
fat transport. Pharmacol Rev 12:241—263, 1960
32. BENGTSSON 0, OLIVECRONA TH: Lipoprotein lipase: Some effects
of activator proteins. Eur J Biochem 106:549—555, 1980
33, KERN PA, MARTIN RA, CARTY J, GOLDBERG Ii, ONG JM: Identi-
fication of lipoprotein lipase immunoreactive protein in pre- and
postheparin plasma from normal subjects and patients with type I
hyperlipoproteinemia. J Lipid Res 31:17—26, 1990
34. BABIRAK SP, IVERIU5 PH, FUJIMOTO WY, BRUNZELL JD Detec-
tion and characterization of the heterozygote state for lipoprotein
lipase (LPL) deficiency. Arteriosclerosis 9:326—334, 1989
35. CHENG FCH, BENSADOUN A, BERSOT T, Hsu JST, MELFORD KH:
Purification and characterization of human lipoprotein lipase and
hepatic triglyceride lipase. J Biol Chem 260:10720—10727, 1985
36. NILSSON-EHLE P: Measurements of lipoprotein lipase activity, in
Lipoprotein Lipase, edited by BORENSZTAJN J, Chicago, Evner
Publishers Inc., 1987, pp. 59—77
37. GOLDBERG U, PATERNITI JR. FRANCE DS, MARTINELLI G, C0R-
NICELLI JA: Production and use of an inhibitory monoclonal
antibody to human lipoprotein lipase. Elsevier 1986, pp. 168—176
38. NIKKILA EA, Kuusi T, TASKINEN MR: Role of lipoprotein lipase
and hepatic endothelial lipase in the metabolism of high density
lipoproteins. A novel concept on cholesterol transport in HDL-
cycle, in Metabolic Risk Factors in Ischemic Cardiovascular Dis-
ease, New York, Raven Press, 1982, pp. 205—215
39. NIKKILA EA: Familial lipoprotein lipase deficiency and related
disorders of chylomicron metabolism, in The Metabolic Basis of
Inherited Disease, edited by STANBURY JB, WYNGAARDEN JB,
FREDRICKSON DS, GOLDSTEIN JL, BROWN MS. New York, Mc-
Graw Hill Book Company, 1983, pp. 622—642
40. BRECKENRIDGE WC: Deficiencies of plasma lipolytic activities.
AmHeartJ 113:567—573, 1987
41. APPLEBAUM-BOWDEN D, HAFFNER STM, WAHL PW, HOOVER JJ,
WARNICK GR, ALBERS JJ, HAZZARD WR: Postheparin plasma
triglyceride lipases. Relationships with very low density lipoprotein
triglyceride and high density lipoprotein2 cholesterol. Arterioscle-
rosis 5:273—282, 1985
42. LEVY RI, BRENSIKE JF, EPSTEIN STE, KELSEY SF, PASSMANI ER,
RICHARDSON JM, LOU 1K, STONE NJ, ALDRICH RF, BATTAGLINI
JW, MORIATY DJ, FISHER ML, FRIEDMAN L, FRIEDEWALD W,
DETRE KM: The influence of changes in lipid values induced by
cholestyramine and diet on progression of coronary artery disease:
Results of NHLBI typ II coronary intervention study. Circulation
69:325—337, 1984
43. BE1-FERIDGE DJ: Lipids, diabetes, and vascular disease: The time
to act. Diabetic Med 6:195—218, 1989
44. KANNEL WB: Lipids, diabetes, and coronary heart disease: In-
sights from the Framingham Study. Am Heart J 110:1100—1107,
1985
45. WALDHAUSL W, BRATUSCH-MARRAIN P. GASIC 5, KORN A, No-
WOTNY P: Insulin production rate following glucose ingestion
estimated by splanchnic C-peptide output in normal man. Diabeto-
logia 17:221—227, 1979
46. LIPID RESEARCH CLINICS—CORONARY PRIMARY PREVENTION
TRIAL RESULTS: II. The relationship of reduction in incidence of
coronary heart disease to cholesterol lowering. J Am Med Assoc
251:365—374, 1984
47. KRAUSS RM, LEVY RI, FREDRICKSON DS: Selective measurement
of two lipase activities in postheparin plasma from normal subjects
and patients with hyperlipoproteinemia. I Clin Invest 54:1107—1124,
1974
48. SAS INSTITUTE INC. STAFF: SAS Users Guide: Statistics. Version
5. Rev. ed Cary N.C.; SAS Institute, 1985
49. SAS INSTITUTE INC.: SUGI Supplemental Library Users Guide.
Version 5 Rev. ed Cary N.C.; SAS Institute, 1985
50. CRAWFORD GA, SAVDIE E, STEWART JH: 1-leparin-released
plasma lipases in chronic renal failure and after renal transplanta-
tion. Clin Sci 57:155—165, 1979
51. IBELS L, REARDON MF, NESTEL PJ: Plasma post-heparin lipolytic
activity and triglyceride clearance in uremic and hemodialysis
patients and renal allograft recipients. I Lab Clin Med 87 (Suppl
4):648—658, 1976
52. DRUML W, ZECHNER R, MAGOMETSCHNIGG D, LENZ K, KLEIN-
BERGER G, LAGGNER A, KOSTNER G: Post-heparin lipolytic activity
in acute renal failure. Clin Nephrol 23:289—293, 1985
53. DRUML W, LAGGNER A, WIDHALM K, KLEINBERGER 0, LENZ K:
Lipid metabolism in acute renal failure. Kidney Jut 24:139—142,
1983
54. HU-I-FUNEN JK, EHNHOLM C, KEKKI M, NIKKILA EA: Post-
heparin plasma lipoprotein lipase in normal subjects and in patients
with hypertriglyceridaemia: Correlation to sex, age and various
parameters of triglyceride metabolism. Clin Sci Mo! Med 50:249—
260, 1976
55. BRODOWS RG, CAMPBELL RG: Effect of age on post-heparin lipase.
N Eng! J Med 287 (Suppl 19):969—970, 1972
56. VAZIRI ND, RISK C, HARTIN DC, NOVEY HS: Comparison of
hyperlipidemia in dialysis patients, renal transplant recipients and
steroid treated nonrenal patients. J Dial Transplant 4:63—71, 1980
57. DURRINGTON PN: Secondary hyperlipidemia, in Hyperlipidemia:
Diagnosis and Management, edited by WRIGHT, London, Butter-
worth & Co., 11:219—276, 1989
58. SADUR CN, ECKEL RH: Insulin stimulation of adipose tissue
lipoprotein lipase. iC/in Invest 69:1119—1125, 1982
59. O'LOONEY PA, VAHOUNY GV: Diabetes and lipoprotein lipase
activity, in Lipoprotein Lipase (vol 9), edited by BOREUSZTAJN,
Chicago, Evener Publishers, 1987, 229—246
60. RANDLE PJ, GARLAND PB, HAALES CN, NEWSHOLME EA: The
glucose fatty-acid cycle. Its role in insulin sensitivity and metabolic
disturbances of diabetes mellitus. Lancet 1:785—789, 1963
61. KERN PA, ONG IM, SAFFARI B, CARTY J: The effects of weight loss
on the activity and expression of adipose tissue lipoprotein lipase in
very obese humans. N Engl J Med 322:1053—1059, 1990
62. KAYSEN GA, GAMBERTOGLIO J, FELTS J, HUTCHISON FN: Albu-
min synthesis, albuminuria and hyperlipidemia in nephrotic pa-
tients. Kidney Jut 31:1368—1376, 1987
63. DURRINGTON PN: Lipoproteins and their metabolism, in Hyperlip-
idemia: Diagnosis and Management (vol 2), edited by WRIGHT,
London, Butterworth & Co Publ., 1989, pp. 23—55
64. DE GROEN PC: Cyclosporine, low-density lipoprotein, and choles-
terol. Mayo Clin Proc 63:1012—1021, 1988
65. SANGHVI A, WARTY V, ZEEVI A, DIVEN W, DUQUESNOY R,
MAKOWKA L, STARZL TE: FK-506 enhances cyclosporine uptake
by peripheral blood lymphocytes. Transplant Proc 19 (Suppl 6):45—
49, 1987
66. HOFMANN SL, RUSSEL DW, GOLDSTEIN JL, BROWN MS: mRNA
for low density lipoprotein receptors in brain and spinal cord of
immature and mature rabbits. Proc Nat! Acad Sci USA 84:63 12—
6316, 1987
67. KRONKE M, LEONARD WJ, DEPPER JM: Cyclosporine A inhibits
T-cell growth factor gene expression at the level of mRNA tran-
scription. Proc Nat! Acad Sci USA 81:5214—5218, l984
